(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Canopy Growth, Senmiao Technology Limited, and ACM Research.

The three biggest losers today are Tattooed Chef, AGBA Acquisition Limited, and VBI Vaccines.

Winners today

1. Canopy Growth (CGC) – 52.1%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth jumping 52.1% to $0.59 on Tuesday while NASDAQ rose 0.21% to $13,816.77.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-4.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -151.11%.

Volatility

Canopy Growth’s last week, last month’s, and last quarter’s current intraday variation average was a negative 7.12%, a negative 3.82%, and a positive 4.08%.

Canopy Growth’s highest amplitude of average volatility was 8.00% (last week), 5.08% (last month), and 4.08% (last quarter).

Previous days news about Canopy Growth

• Canopy growth (cgc) improves liquidity with another selloff. According to Zacks on Monday, 3 July, "As a result, Canopy Growth is now better positioned to achieve its goal of becoming an asset-light, North America-focused cannabis business.", "As the cannabis industry continues to evolve, Canopy Growth remains committed to delivering innovative products that enhance the lives of consumers while creating sustainable value for shareholders."

More news about Canopy Growth.

2. Senmiao Technology Limited (AIHS) – 16.19%

Senmiao Technology Limited engages in the automobile transaction and related services business in the People's Republic of China. Its services include the facilitation of automobile transaction and financing, connecting ride-hailing drivers to financial institutions to buy, or get financing on the purchase of, cars to be used to provide ride-hailing services. The company is also involved in the sale of automobiles; and provision of auto finance services. Senmiao Technology has strategic cooperation with Gaode Map for utilization in ride sharing initiatives. Senmiao Technology Limited was incorporated in 2017 and is based in Chengdu, the People's Republic of China.

NASDAQ ended the session with Senmiao Technology Limited rising 16.19% to $0.54 on Tuesday while NASDAQ rose 0.21% to $13,816.77.

Earnings Per Share

As for profitability, Senmiao Technology Limited has a trailing twelve months EPS of $-1.21.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -50.8%.

Volume

Today’s last reported volume for Senmiao Technology Limited is 18387 which is 65.31% below its average volume of 53008.

Yearly Top and Bottom Value

Senmiao Technology Limited’s stock is valued at $0.54 at 17:32 EST, way under its 52-week high of $1.97 and way higher than its 52-week low of $0.45.

Moving Average

Senmiao Technology Limited’s worth is way below its 50-day moving average of $0.79 and way below its 200-day moving average of $0.87.

Revenue Growth

Year-on-year quarterly revenue growth grew by 4.9%, now sitting on 8.08M for the twelve trailing months.

More news about Senmiao Technology Limited.

3. ACM Research (ACMR) – 13.38%

ACM Research, Inc., together with its subsidiaries, develops, manufactures, and sells single-wafer wet cleaning equipment for enhancing the manufacturing process and yield for integrated chips worldwide. It offers space alternated phase shift technology for flat and patterned wafer surfaces, which employs alternating phases of megasonic waves to deliver megasonic energy in a uniform manner on a microscopic level; timely energized bubble oscillation technology for patterned wafer surfaces at advanced process nodes, which provides cleaning for 2D and 3D patterned wafers with fine feature sizes; Tahoe technology for delivering cleaning performance using less sulfuric acid and hydrogen peroxide; and electro-chemical plating technology for advanced metal plating. The company markets and sells its products under the Ultra C brand name through direct sales force and third-party representatives. ACM Research, Inc. was incorporated in 1998 and is headquartered in Fremont, California.

NASDAQ ended the session with ACM Research rising 13.38% to $14.83 on Tuesday, following the last session’s upward trend. NASDAQ rose 0.21% to $13,816.77, after two successive sessions in a row of gains, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, ACM Research has a trailing twelve months EPS of $0.86.

PE Ratio

ACM Research has a trailing twelve months price to earnings ratio of 17.24. Meaning, the purchaser of the share is investing $17.24 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.16%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 76%, now sitting on 420.9M for the twelve trailing months.

More news about ACM Research.

4. Vascular Biogenics Ltd. (VBLT) – 12.96%

Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; and VB-703 for NASH and renal fibrosis. In addition, the company is developing VB-201, a Lecinoxoid-based product candidate to treat atherosclerosis that has completed Phase II clinical; and is in Phase II exploratory trials for COVID-19, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

NASDAQ ended the session with Vascular Biogenics Ltd. rising 12.96% to $0.26 on Tuesday, following the last session’s upward trend. NASDAQ rose 0.21% to $13,816.77, after two sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Vascular Biogenics Ltd. has a trailing twelve months EPS of $-0.32.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -78.2%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Vascular Biogenics Ltd.’s EBITDA is 3.23.

Yearly Top and Bottom Value

Vascular Biogenics Ltd.’s stock is valued at $0.26 at 17:32 EST, way under its 52-week high of $2.20 and way higher than its 52-week low of $0.10.

Moving Average

Vascular Biogenics Ltd.’s value is way higher than its 50-day moving average of $0.21 and way higher than its 200-day moving average of $0.17.

Volume

Today’s last reported volume for Vascular Biogenics Ltd. is 1507740 which is 1.93% above its average volume of 1479060.

More news about Vascular Biogenics Ltd..

5. Riot Blockchain (RIOT) – 12.94%

Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. It operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. The company also provides co-location services for institutional-scale bitcoin mining companies; and critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners. In addition, it engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy; operation of data centers; and maintenance/management of computing capacity. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain jumping 12.94% to $13.35 on Tuesday, after three consecutive sessions in a row of gains. NASDAQ jumped 0.21% to $13,816.77, after two consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-4.29.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -48.54%.

Moving Average

Riot Blockchain’s value is way higher than its 50-day moving average of $11.12 and way higher than its 200-day moving average of $7.55.

Volatility

Riot Blockchain’s last week, last month’s, and last quarter’s current intraday variation average was 3.60%, 0.69%, and 5.07%.

Riot Blockchain’s highest amplitude of average volatility was 4.08% (last week), 3.95% (last month), and 5.07% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Riot Blockchain’s EBITDA is -683.8.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 91.8% and 12.5%, respectively.

More news about Riot Blockchain.

6. Coinbase (COIN) – 11.71%

Coinbase Global, Inc. provides financial infrastructure and technology for the cryptoeconomy in the United States and internationally. It offers the primary financial account in the cryptoeconomy for consumers; a marketplace with a pool of liquidity for transacting in crypto assets for institutions; and technology and services that enable developers to build crypto-based applications and securely accept crypto assets as payment. The company was founded in 2012 and is based in Wilmington, Delaware.

NASDAQ ended the session with Coinbase rising 11.71% to $79.93 on Tuesday while NASDAQ rose 0.21% to $13,816.77.

Earnings Per Share

As for profitability, Coinbase has a trailing twelve months EPS of $-11.5.

Volume

Today’s last reported volume for Coinbase is 19623700 which is 29.98% above its average volume of 15096400.

Volatility

Coinbase’s last week, last month’s, and last quarter’s current intraday variation average was 0.79%, 0.53%, and 4.02%.

Coinbase’s highest amplitude of average volatility was 1.61% (last week), 4.15% (last month), and 4.02% (last quarter).

Sales Growth

Coinbase’s sales growth is negative 49% for the ongoing quarter and 38.3% for the next.

More news about Coinbase.

7. Addex Therapeutics Ltd (ADXN) – 11.42%

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health; and research collaboration agreement with Indivior PLC. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

NASDAQ ended the session with Addex Therapeutics Ltd jumping 11.42% to $0.58 on Tuesday while NASDAQ jumped 0.21% to $13,816.77.

Earnings Per Share

As for profitability, Addex Therapeutics Ltd has a trailing twelve months EPS of $-2.34.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -204.24%.

Moving Average

Addex Therapeutics Ltd’s worth is way under its 50-day moving average of $0.71 and way under its 200-day moving average of $0.90.

Revenue Growth

Year-on-year quarterly revenue growth grew by 105.8%, now sitting on 1.7M for the twelve trailing months.

Volume

Today’s last reported volume for Addex Therapeutics Ltd is 108684 which is 77.39% below its average volume of 480822.

More news about Addex Therapeutics Ltd.

8. Marathon (MARA) – 10.53%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.

NASDAQ ended the session with Marathon jumping 10.53% to $15.32 on Tuesday, after three successive sessions in a row of gains. NASDAQ jumped 0.21% to $13,816.77, after two consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-6.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -103.2%.

Volatility

Marathon’s last week, last month’s, and last quarter’s current intraday variation average was 3.54%, 2.26%, and 5.80%.

Marathon’s highest amplitude of average volatility was 4.38% (last week), 5.61% (last month), and 5.80% (last quarter).

More news about Marathon.

9. MicroStrategy (MSTR) – 10.34%

MicroStrategy Incorporated provides enterprise analytics software and services in the United States, Canada, Europe, the Middle East, Africa, and internationally. It offers MicroStrategy, an enterprise analytics software platform that enables users to create visualizations, customize apps, and embed analytics directly into workflows; and MicroStrategy Cloud Environment, a managed software-as-a-service solution, which offers always-on threat monitoring and enables rapid analytics development and deployment to deliver security and data privacy requirements. The company also provides MicroStrategy Support that helps customers to achieve their system availability and uptime goals, and to improve the overall experience through highly responsive troubleshooting and proactive technical product support. In addition, it offers MicroStrategy Consulting, which offers customers with architecture and implementation services to help them quickly realize results, as well as helps to achieve returns on investment derived from understanding of data; and MicroStrategy Education that provides free and paid learning options, as well as holds and acquires bitcoin. The company offers its services through enterprise sales force and channel partners. It serves companies from a range of industries, including banking, technology, consulting, manufacturing, insurance, healthcare, and telecommunications, as well as the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.

NASDAQ ended the session with MicroStrategy jumping 10.34% to $377.84 on Tuesday while NASDAQ jumped 0.21% to $13,816.77.

Earnings Per Share

As for profitability, MicroStrategy has a trailing twelve months EPS of $-85.35.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -134.41%.

More news about MicroStrategy.

10. Universal Stainless & Alloy Products (USAP) – 9.21%

Universal Stainless & Alloy Products, Inc., together with its subsidiaries, manufactures and markets semi-finished and finished specialty steel products in the United States and internationally. Its products include stainless steel, nickel alloys, tool steel, and various other alloyed steels. The company offers semi-finished and finished long products in the form of ingots, blooms, billets, and bars; flat rolled products, such as slabs and plates; and customized shapes primarily for original equipment manufacturers (OEMs), which are cold rolled from purchased coiled strip, flat bar, or extruded bar. Its semi-finished long products are primarily used to produce rods; and finished bar products that are principally used by OEMs and by service center customers for distribution to various end users. The company also offers conversion services on materials supplied by its customers. Its products are used in aerospace, power generation, oil and gas, heavy equipment, general, and automotive industries, as well as in the manufacturing of equipment for food handling, health and medical, chemical processing, and pollution control; and manufacturing of metals, plastics, paper and aluminum extrusions, pharmaceuticals, electronics, and optics. The company sells its products to service centers, forgers, rerollers, and OEMs. Universal Stainless & Alloy Products, Inc. was founded in 1994 and is headquartered in Bridgeville, Pennsylvania.

NASDAQ ended the session with Universal Stainless & Alloy Products rising 9.21% to $15.30 on Tuesday while NASDAQ rose 0.21% to $13,816.77.

Earnings Per Share

As for profitability, Universal Stainless & Alloy Products has a trailing twelve months EPS of $-0.78.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.14%.

Sales Growth

Universal Stainless & Alloy Products’s sales growth is 27.4% for the current quarter and 48.1% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Universal Stainless & Alloy Products’s EBITDA is 28.04.

Moving Average

Universal Stainless & Alloy Products’s value is way above its 50-day moving average of $11.02 and way higher than its 200-day moving average of $8.63.

More news about Universal Stainless & Alloy Products.

Losers Today

1. Tattooed Chef (TTCF) – -46.79%

Tattooed Chef, Inc., a plant-based food company, produces and sells a portfolio of frozen foods. It supplies plant-based products to retailers in the United States. The company offers ready-to-cook bowls, zucchini spirals, riced cauliflower, acai and smoothie bowls, cauliflower crust pizza, wood fire crusted pizza, handheld burritos, and bars and quesadillas. Its products are available in private label and Tattooed Chef brand name in the frozen food section of retail food stores, as well as online. Tattooed Chef, Inc. is headquartered in Paramount, California.

NASDAQ ended the session with Tattooed Chef falling 46.79% to $0.29 on Tuesday while NASDAQ rose 0.21% to $13,816.77.

Earnings Per Share

As for profitability, Tattooed Chef has a trailing twelve months EPS of $-1.7.

Volume

Today’s last reported volume for Tattooed Chef is 7595250 which is 542.24% above its average volume of 1182600.

Volatility

Tattooed Chef’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.35%, a negative 0.25%, and a positive 4.97%.

Tattooed Chef’s highest amplitude of average volatility was 2.96% (last week), 3.23% (last month), and 4.97% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Tattooed Chef’s stock is considered to be oversold (<=20).

More news about Tattooed Chef.

2. AGBA Acquisition Limited (AGBAW) – -41.5%

AGBA Group Holding Limited focuses on operating a full-service platform to banks, other financial institutions, brokers, and individual financial advisors to advise and serve its retail clients. The company offers a range of financial products, such as life insurance, pensions, property-casualty insurance, mutual funds, money lending, and real estate agency services. It also operates an health and wealth management platform that offers a range of services and value-added information in health, insurance, investments, and social sharing. The company is based in Wan Chai, Wan Chai.

NASDAQ ended the session with AGBA Acquisition Limited sliding 41.5% to $0.04 on Tuesday while NASDAQ jumped 0.21% to $13,816.77.

Yearly Top and Bottom Value

AGBA Acquisition Limited’s stock is valued at $0.04 at 17:32 EST, way below its 52-week high of $0.06 and way above its 52-week low of $0.03.

More news about AGBA Acquisition Limited.

3. VBI Vaccines (VBIV) – -19.76%

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. The company primarily serves physicians and pharmacists through direct sales. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition For Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with VBI Vaccines falling 19.76% to $2.64 on Tuesday while NASDAQ jumped 0.21% to $13,816.77.

Earnings Per Share

As for profitability, VBI Vaccines has a trailing twelve months EPS of $-11.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -137.24%.

More news about VBI Vaccines.

4. AGM Group Holdings (AGMH) – -12.7%

AGM Group Holdings Inc., an integrated technology company, focuses on ASIC chip solutions. Its ASIC chip solutions include chip design, chip research and development, and crypto miner production. It also provides fintech software services. The company offers multi-assets trading and management systems to small and mid-size broker and institutional clients; and interactive trading education website that uses subscription-based method. Its FXSC is an online trading education and social trading network platform for forex traders; and provides trading education to users through interactive trading simulation and trading contests, as well as demo trading services. In addition, the company sells technical support plans; and delivers software customization services. The company was incorporated in 2015 and is based in Wan Chai, Hong Kong.

NASDAQ ended the session with AGM Group Holdings sliding 12.7% to $1.65 on Tuesday, after four successive sessions in a row of losses. NASDAQ rose 0.21% to $13,816.77, after two successive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, AGM Group Holdings has a trailing twelve months EPS of $0.88.

PE Ratio

AGM Group Holdings has a trailing twelve months price to earnings ratio of 1.88. Meaning, the purchaser of the share is investing $1.88 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 96.82%.

Volume

Today’s last reported volume for AGM Group Holdings is 3070 which is 44.26% below its average volume of 5508.

More news about AGM Group Holdings.

5. Astrazeneca (AZN) – -8.83%

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

NYSE ended the session with Astrazeneca sliding 8.83% to $65.25 on Tuesday, following the last session’s downward trend. NYSE jumped 0.27% to $15,918.50, after three consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Astrazeneca has a trailing twelve months EPS of $1.53.

PE Ratio

Astrazeneca has a trailing twelve months price to earnings ratio of 42.65. Meaning, the purchaser of the share is investing $42.65 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.05%.

Yearly Top and Bottom Value

Astrazeneca’s stock is valued at $65.25 at 17:32 EST, way below its 52-week high of $76.56 and way higher than its 52-week low of $52.65.

More news about Astrazeneca.

6. XOMA Corporation (XOMA) – -6.72%

XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and X213, an allosteric inhibitor of prolactin action;. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; Takeda Pharmaceutical Company Limited; and Cadila Healthcare Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

NASDAQ ended the session with XOMA Corporation dropping 6.72% to $17.62 on Tuesday while NASDAQ jumped 0.21% to $13,816.77.

Earnings Per Share

As for profitability, XOMA Corporation has a trailing twelve months EPS of $-2.64.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -19.36%.

More news about XOMA Corporation.

7. BlackBerry (BB) – -5.24%

NYSE ended the session with BlackBerry sliding 5.24% to $5.24 on Tuesday, after two successive sessions in a row of losses. NYSE rose 0.27% to $15,918.50, after three consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BlackBerry’s stock is considered to be oversold (<=20).

Volatility

BlackBerry’s last week, last month’s, and last quarter’s current intraday variation average was 3.12%, 0.23%, and 2.14%.

BlackBerry’s highest amplitude of average volatility was 3.65% (last week), 2.11% (last month), and 2.14% (last quarter).

More news about BlackBerry.

8. Smith & Nephew (SNN) – -5.12%

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

NYSE ended the session with Smith & Nephew sliding 5.12% to $30.60 on Tuesday, after two sequential sessions in a row of losses. NYSE jumped 0.27% to $15,918.50, after three successive sessions in a row of gains, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Smith & Nephew has a trailing twelve months EPS of $0.51.

PE Ratio

Smith & Nephew has a trailing twelve months price to earnings ratio of 60. Meaning, the purchaser of the share is investing $60 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.12%.

Volatility

Smith & Nephew’s last week, last month’s, and last quarter’s current intraday variation average was 0.53%, 0.32%, and 0.99%.

Smith & Nephew’s highest amplitude of average volatility was 1.53% (last week), 1.07% (last month), and 0.99% (last quarter).

Volume

Today’s last reported volume for Smith & Nephew is 1425470 which is 60.32% above its average volume of 889104.

More news about Smith & Nephew.

9. Catalyst Pharmaceuticals (CPRX) – -5.06%

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

NASDAQ ended the session with Catalyst Pharmaceuticals dropping 5.06% to $12.76 on Tuesday while NASDAQ rose 0.21% to $13,816.77.

Earnings Per Share

As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.89.

PE Ratio

Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 14.34. Meaning, the purchaser of the share is investing $14.34 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.89%.

Sales Growth

Catalyst Pharmaceuticals’s sales growth is 74.1% for the present quarter and 83.2% for the next.

Moving Average

Catalyst Pharmaceuticals’s value is under its 50-day moving average of $13.66 and way below its 200-day moving average of $15.26.

More news about Catalyst Pharmaceuticals.

10. Viking Therapeutics (VKTX) – -4.75%

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

NASDAQ ended the session with Viking Therapeutics sliding 4.75% to $15.44 on Tuesday, following the last session’s downward trend. NASDAQ rose 0.21% to $13,816.77, after two consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.77.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.71%.

Volume

Today’s last reported volume for Viking Therapeutics is 1557750 which is 56.77% below its average volume of 3604200.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Viking Therapeutics’s EBITDA is -56.81.

Yearly Top and Bottom Value

Viking Therapeutics’s stock is valued at $15.44 at 17:32 EST, way under its 52-week high of $25.72 and way above its 52-week low of $2.54.

More news about Viking Therapeutics.

Stay up to date with our winners and losers daily report